GLP1R and obesity due to melanocortin 4 receptor deficiency: In 2014, the U.S. Food and Drug Administration (FDA) granted approval for Saxenda as the first GLP-1 RA medication that can be used in conjunction with a low-calorie diet and regular exercise for obesity treatment in adults.